SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Goldman Sachs Maintains Buy Rating on InnoCare Pharma

Goldman Sachs maintained its Buy rating on InnoCare Pharma.

Related stories